The FDA approved Vitestro’s Aletta, described as the first standalone robotic device in the U.S. designed to draw blood with limited hands-on assistance. The device performs key steps—tourniquet placement through bandaging—while using multimodal imaging and Doppler ultrasound to identify veins and avoid arteries. In Vitestro’s reported results from a key trial, Aletta achieved a 94.5% first-stick success rate, and about 90% of participants reported pain levels that were less than or similar to manual blood draws. FDA also highlighted ongoing phlebotomist shortages and framed the approval as a step to reduce delays in outpatient settings. Aletta has already been approved in Europe for about two years, and the company previously raised $70 million in an oversubscribed Series B round. Funding is earmarked for manufacturing scale-up, clinical expansion, and commercialization as Vitestro prepares for broader market adoption. For biotech and medtech, the clearance matters because it links device automation to measurable clinical workflow performance—first-stick success and pain outcomes—rather than focusing solely on operational convenience.